IL28B polymorphism and virological responseduring 12 weeks of pegylated interferon and ribavirin treatment in Polish chronic hepatitis C patients.

MLA

Świątek, B., et al. “IL28B Polymorphism and Virological Responseduring 12 Weeks of Pegylated Interferon and Ribavirin Treatment in Polish Chronic Hepatitis C Patients.” International Journal of Infectious Diseases, vol. 21, Apr. 2014, p. 313. EBSCOhost, https://doi.org/10.1016/j.ijid.2014.03.1069.

APA

Świątek, B., Januszkiewicz, D., Rembowska, J., Bereszyńska, I., Kowala-Piaskowska, A., Mozer-Lisewska, I., Wysocki, J., & Nowak, J. (2014). IL28B polymorphism and virological responseduring 12 weeks of pegylated interferon and ribavirin treatment in Polish chronic hepatitis C patients. International Journal of Infectious Diseases, 21, 313. https://doi.org/10.1016/j.ijid.2014.03.1069

Chicago

Świątek, B., D. Januszkiewicz, J. Rembowska, I. Bereszyńska, A. Kowala-Piaskowska, I. Mozer-Lisewska, J. Wysocki, and J. Nowak. 2014. “IL28B Polymorphism and Virological Responseduring 12 Weeks of Pegylated Interferon and Ribavirin Treatment in Polish Chronic Hepatitis C Patients.” International Journal of Infectious Diseases 21 (April): 313. doi:10.1016/j.ijid.2014.03.1069.